Testicular Cancer References

REFERENCES

Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. European Association of Urology. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Testicular-Cancer-2015-v2.pdf. 2015.
Motzer RJ, Feldman DR, Bosl GJ. Testicular cancer. In: Kasper DL, Fauci AS, Hauser SL, et al, eds. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill; 2015:588-592.
National Cancer Institute: PDQ® Testicular cancer treatment - for health professionals. Bethesda, MD: National Cancer Institute. http://www.cancer.gov/types/testicular/hp/testicular-treatment-pdq. 01 Oct 2015.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: testicular cancer version 1.2016. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. 03 Nov 2015.
Oh WK. Overview of the treatment of testicular germ cell tumors. UpToDate. http://www.uptodate.com/contents/overview-of-the-treatment-of-testicular-germ-cell-tumors. 18 Jun 2015.
Oldenburg J, Fosså SD, Nuver J, et al; ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi125-132. doi: 10.1093/annonc/mdt304. PMID: 24078656
Steele GS, Richie JP, Oh WK, et al. Clinical manifestations, diagnosis, and staging of testicular germ cell tumors. UpToDate. http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-testicular-germ-cell-tumors. 18 Sep 2015.
Cancer Therapy Advisor. Testicular cancer treatment regimens. Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/. Nov 2019.
Honecker F, Aparicio J, Berney D, et al. ESMO consensus conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018 Aug;29(8):1658-1686. doi: 10.1093/annonc/mdy217. PMID: 30113631
Laguna MP, Albers P, Algaba F, et al. EAU guidelines on testicular cancer. European Association of Eurology. https://www.uroweb.org/. Mar 2022.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Testicular cancer. NCCN. https://www.nccn.org/. 04 Jan 2022.
Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Apr;33(4):362-375. doi: 10.1016/j.annonc.2022.01.002. PMID: 35065204
Oh WK. Overview of the treatment of testicular germ cell tumors. UpToDate. https://www.uptodate.com. 08 Apr 2022.
PDQ® Screening and Prevention Editorial Board. PDQ testicular cancer screening. National Cancer Institute. Bethesa, MD; 2022 Feb. https://www.cancer.gov/.
Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019 Aug;202(2):272-281. doi: 10.1097/JU.0000000000000318. PMID: 31059667

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.